Understanding Brain Reward Responses in Individuals With Major Depressive Disorder
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00183755 |
|
Recruitment Status :
Completed
First Posted : September 16, 2005
Last Update Posted : April 21, 2014
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease |
|---|
| Depression |
Major depressive disorder (MDD) is a severe form of depression that can significantly interfere with an individual's thoughts, behavior, mood, and physical health. People who suffer from MDD may experience anhedonia, or the inability to gain pleasure from normally pleasurable experiences. Such individuals do not respond to motivational rewards in the same way as do individuals who are not depressed. Anhedonia has been recognized as a core symptom of depression and it is not always remedied with antidepressant medication. Abnormal brain activity and processing may be the underlying cause of depression and specifically anhedonia. A better understanding of the brain mechanisms of depression may lead to the development of new effective medications or psychological treatments.
Event-related potential (ERP), which measures electrical activity in the brain, and functional magnetic resonance imaging (fMRI), which uses scanned images to illustrate changes in brain activity, are two techniques that can identify abnormal areas of brain processing. The purpose of this study is to use ERP and fMRI to compare brain activity that is related to reward processing in individuals with MDD versus individuals without MDD.
This study will consist of 3 study visits; visits will be scheduled as close together as possible. At the first study visit, potential participants will be assessed with the SCID (Structured Clinical Interview for DSM-IV), which will identify individuals with the diagnostic criteria for MDD. A control group of non-depressed individuals will also be enrolled in the study. During the second and third study visits, participants will take part in a monetary reinforcement reward task followed by a signal detection reward task. Brain activity of all participants will be monitored during both tasks. During the second study visit, ERP will be used; during the third study visit, fMRI will be used. Demographic information will also be collected, and participants will complete several standardized questionnaires to assess mood. Some participants will be asked to return after eight weeks to complete the fMRI and EEG sessions again. Those who do complete all five sessions will be awarded a bonus.
| Study Type : | Observational |
| Actual Enrollment : | 87 participants |
| Observational Model: | Cohort |
| Time Perspective: | Prospective |
| Official Title: | Neuroimaging Studies of Reward Processing in Depression |
| Study Start Date : | April 2005 |
| Actual Primary Completion Date : | April 2009 |
| Actual Study Completion Date : | April 2009 |
| Group/Cohort |
|---|
|
1
Control participants
|
|
2
Participants with MDD
|
- Performance on Monetary Incentive Delay task [ Time Frame: Given once during the second session for half an hour, and once during the third session for half an hour ]This task features balanced incentive delivery and analytic strategies designed to identify activity specific to anticipation or consumption of incentives.
- Signal detection reward task [ Time Frame: Given once during the second session for fifteen minutes, and once during the third session for fifteen minutes ]This reward task provides an objective assessment of hedonic capacity. Due to the probabilistic nature of the task, participants cannot infer which stimulus is more advantageous based on the outcome of single trials but need to integrate reinforcement history over time to optimize behavior.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 64 Years (Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Probability Sample |
Overall Inclusion Criteria:
- Right-handed
- Agrees to use an effective form of contraception throughout the study
Inclusion Criteria for Depressed Participants:
- Meets overall inclusion criteria
- Meets DSM-IV diagnosis criteria for major depressive disorder
- Score of at least 16 on the 21-item HAM-D scale
Overall Exclusion Criteria:
- Left-handed or ambidextrous
- Claustrophobic
- Neurological or medical illness (e.g., attention deficit hyperactivity disorder, head injury, loss of consciousness, seizures)
- Pregnant
Exclusion Criteria for Depressed Participants:
- Meets any of the overall exclusion criteria
- Has been treated with electroconvulsive therapy within 6 months of study entry
- Has taken any benzodiazepine medications for at least 2 weeks prior to study entry and discontinued use of the medication for reasons other than participating in the study
- Has taken any dopaminergic medications (including methylphenidate) or neuroleptics for at least 6 months prior to study entry and discontinued use of the medication for reasons other than participating in the study
- Has taken any fluoxetine medications for at least 6 weeks prior to study entry and discontinued use of the medication for reasons other than participating in the study
- Has taken any medications that may have antidepressant properties (including some herbal supplements) within 2 weeks of study entry
- Has taken any medications that may affect blood flow (including some blood pressure medications) within 2 weeks of study entry
- Current or past history of MDD with psychotic features
- Meets DSM-IV diagnosis criteria for organic mental disorder; substance use disorder (within 1 year of study entry); lifetime substance dependence; schizophrenia; delusional disorder; bipolar disorder; post-traumatic stress disorder; eating disorder; acute bereavement; severe borderline or antisocial personality disorder; or any psychotic disorder not otherwise specified
- Current primary diagnosis of panic disorder, social phobia, generalized anxiety disorder, obsessive-compulsive disorder, or somatoform disorder
Exclusion Criteria for Control Participants
- Meets any of the overall exclusion criteria
- Diagnosed with any medical or neurological illness
- Diagnosed with any current or past psychiatric illness, as assessed by the SCID-I, including substance abuse or dependence (e.g., alcohol)
- Has taken any medications that may have antidepressant properties (including some herbal supplements) within 2 weeks of study entry
- Has taken any psychotropic medications within 2 weeks of study entry
- Has taken any medications that may affect blood flow (including some blood pressure medications) within 2 weeks of study entry
Exclusion Criteria for fMRI Studies:
- Meets any of the overall exclusion criteria
- Fails to meet safety standards for fMRI
- Current back problems
- Has strongly corrected vision, but does not wear contact lenses
- Weighs more than 250 pounds or exceeds the limit of height-to-weight ratio for a comfortable fit in the scanner
- Pregnant
- Current alcohol or substance abuse
- At risk for suicide or homicide
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00183755
| United States, Massachusetts | |
| The Depression Clinical and Research Program, Massachusetts General Hospital | |
| Boston, Massachusetts, United States, 02114 | |
| Affective Neuroscience Laboratory, Department of Psychology, Harvard University | |
| Cambridge, Massachusetts, United States, 02138 | |
| Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital | |
| Charlestown, Massachusetts, United States, 02129 | |
| Principal Investigator: | Diego A. Pizzagalli, PhD | Harvard University |
Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Diego A. Pizzagalli, Associate Professor, Harvard Medical School, Mclean Hospital |
| ClinicalTrials.gov Identifier: | NCT00183755 History of Changes |
| Other Study ID Numbers: |
R01MH068376 ( U.S. NIH Grant/Contract ) R01MH068376 ( U.S. NIH Grant/Contract ) DATR A3-NSS |
| First Posted: | September 16, 2005 Key Record Dates |
| Last Update Posted: | April 21, 2014 |
| Last Verified: | April 2014 |
Keywords provided by Diego A. Pizzagalli, Mclean Hospital:
|
Reward Processing Anhedonia Major Depressive Disorder Depression |
Additional relevant MeSH terms:
|
Depression Depressive Disorder Depressive Disorder, Major |
Behavioral Symptoms Mood Disorders Mental Disorders |